Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
9.86
+0.08 (0.82%)
Nov 13, 2026, 4:00 PM EST - Market closed
Contineum Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 75.2 | 75.6 | 21.94 | 15.53 | 5.57 | 4.63 |
Short-Term Investments | 169.29 | 187.29 | 182.82 | 109.66 | 41.67 | 64.37 |
Cash & Short-Term Investments | 244.48 | 262.9 | 204.76 | 125.19 | 47.24 | 69 |
Cash Growth | 34.03% | 28.39% | 63.56% | 165.01% | -31.54% | - |
Prepaid Expenses | 5.26 | 5.02 | 1.63 | 2.52 | 1.15 | 0.78 |
Total Current Assets | 249.74 | 267.92 | 206.39 | 127.71 | 48.39 | 69.78 |
Property, Plant & Equipment | 6.94 | 8.47 | 6.46 | 1.4 | 2.12 | 0.64 |
Other Long-Term Assets | 0.3 | 0.26 | 0 | 1.28 | 0.13 | 0.1 |
Total Assets | 256.99 | 276.64 | 212.85 | 130.39 | 50.64 | 70.52 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.64 | 1.02 | 1.81 | 0.64 | 0.43 | 0.66 |
Accrued Expenses | 4.66 | 6.39 | 6.71 | 4.39 | 2.06 | 1.69 |
Current Portion of Long-Term Debt | - | - | - | - | 3.95 | 1.25 |
Current Portion of Leases | 2.72 | 2.34 | 1.45 | 0.46 | 1.11 | - |
Other Current Liabilities | - | - | - | - | - | 0.08 |
Total Current Liabilities | 8.03 | 9.74 | 9.97 | 5.48 | 7.55 | 3.67 |
Long-Term Debt | - | - | - | - | - | 3.66 |
Long-Term Leases | 3.54 | 5.91 | 4.81 | 0.11 | 0.79 | - |
Other Long-Term Liabilities | - | - | - | 0.11 | 3.03 | 1.6 |
Total Liabilities | 11.57 | 15.65 | 14.78 | 5.7 | 11.37 | 8.93 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.04 | 0.04 | 0.03 | 0 | 0.01 | 0.01 |
Additional Paid-In Capital | 472.57 | 438.07 | 315.37 | 7.1 | 4.72 | 2.74 |
Retained Earnings | -225.69 | -177.38 | -117.4 | -75.14 | -97.86 | -73.61 |
Comprehensive Income & Other | -1.51 | 0.26 | 0.07 | 0.11 | -0.08 | -0.04 |
Total Common Equity | 245.42 | 260.99 | 198.07 | -67.94 | -93.21 | -70.89 |
Shareholders' Equity | 245.42 | 260.99 | 198.07 | 124.68 | 39.27 | 61.59 |
Total Liabilities & Equity | 256.99 | 276.64 | 212.85 | 130.39 | 50.64 | 70.52 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 6.27 | 8.25 | 6.26 | 0.57 | 5.85 | 4.91 |
Net Cash (Debt) | 238.22 | 254.65 | 198.5 | 124.62 | 41.39 | 64.1 |
Net Cash Growth | 34.65% | 28.28% | 59.29% | 201.08% | -35.42% | - |
Net Cash Per Share | 6.61 | 9.19 | 10.26 | 36.70 | 18.45 | 30.39 |
Filing Date Shares Outstanding | 39.27 | 37.34 | 25.87 | 2.35 | 2.26 | 2.11 |
Total Common Shares Outstanding | 39.25 | 37.32 | 25.85 | 2.35 | 2.26 | 2.11 |
Working Capital | 241.72 | 258.17 | 196.41 | 122.22 | 40.84 | 66.11 |
Book Value Per Share | 6.25 | 6.99 | 7.66 | -28.91 | -41.25 | -33.61 |
Tangible Book Value | 245.42 | 260.99 | 198.07 | -67.94 | -93.21 | -70.89 |
Tangible Book Value Per Share | 6.25 | 6.99 | 7.66 | -28.91 | -41.25 | -33.61 |
Machinery | - | 2.62 | 2.53 | 2.11 | 1.69 | 1.58 |
Leasehold Improvements | - | 0.18 | 0.18 | 0.05 | 0.02 | 0.02 |